Evidence map›Paper›PMID 38786655›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2024

Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.

Matthew L Edin, Artiom Gruzdev, Joan P Graves, Fred B Lih, Christophe Morisseau, James M Ward, Bruce D Hammock, Catharine M Bosio, Darryl C Zeldin

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew L EdinDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-7042-500X
Artiom GruzdevDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-1698-7159
Joan P GravesDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.
Fred B LihDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-2260-816X
Christophe MorisseauDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, USA.ORCID 0000-0002-5672-6631
James M WardDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-9510-2848
Bruce D HammockDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, USA.ORCID 0000-0003-1408-8317
Catharine M BosioDivision of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.ORCID 0000-0001-9039-6341
Darryl C ZeldinDivision of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-2087-7307

Funding

Characterization And Functional Significance Of P450 Arachidonate EpoxygenasesZIAES025034 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ZELDIN, DARRYL C · 2009 to 2025
$18.6M
Mass Spectrometry QuantitationZICES103005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI WILLIAMS, JASON · 2018 to 2025
$9.2M
P450 Arachidonate EpoxygenasesZ01ES025034 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ZELDIN, DARRYL C · 1995 to 2008
$2.2M
Effect of SARS-CoV-2 on host metabolism and its influence on innate and adaptive immunityZIAAI001281 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BOSIO, CATHARINE · 2020 to 2025
$1.1M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI001281-04Intramural NIH HHS Z01 ES025034NIEHS NIH HHS HHSN273201500013CNIEHS NIH HHS HHSN273201700005CNIEHS NIH HHS HHSN273201800006C
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection involves an initial viral infection phase followed by a host-response phase that includes an eicosanoid and cytokine storm, lung inflammation and respiratory failure. While vaccination and early anti-viral therapies are effective in preventing or limiting the pathogenic host response, this latter phase is poorly understood with no highly effective treatment options. Inhibitors of soluble epoxide hydrolase (sEH) increase levels of anti-inflammatory molecules called epoxyeicosatrienoic acids (EETs). This study aimed to investigate the impact of sEH inhibition on the host response to SARS-CoV-2 infection in a mouse model with human angiotensin-converting enzyme 2 (ACE2) expression. Mice were infected with SARS-CoV-2 and treated with either vehicle or the sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU). At day 5 post-infection, SARS-CoV-2 induced weight loss, clinical signs, a cytokine storm, an eicosanoid storm, and severe lung inflammation with ~50% mortality on days 6-8 post-infection. SARS-CoV-2 infection induced lung expression of phospholipase A

Indexed as

COVID-19Cytokine Release SyndromeEicosanoidsEpoxide HydrolasesPhenylurea CompoundsSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsCOVID-19 Drug TreatmentCytokinesDisease Models, AnimalFemaleHost-Pathogen InteractionsLungMaleMice1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)ureaACE2 protein, humanAngiotensin-Converting Enzyme 2CytokinesEicosanoidsEphx2 protein, mouseEpoxide HydrolasesPhenylurea CompoundsPiperidinesCOVID‐19cytokineseicosanoidsSARS‐CoV‐2soluble epoxide hydrolase

Identifiers

PMID38786655
PMCPMC11141730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.